13.12.2019 | Tracker

FDA Tracker: Oxbryt and Tecentriq discussed the most by healthcare professionals in November

By Nathan Cripps

FDA Tracker: Oxbryt and Tecentriq discussed the most by healthcare professionals in November

CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens. The FDA approved over 940 submissions between November 1 – December 10, which included medicines for sickle cell disease, non-small cell lung cancer (NSCLC) and partial-onset seizures.

The most mentioned FDA approvals by HCPs online

OxbrytvoxelotorGlobal Blood Therapeutics Inc163248
Givlaarigivosiran sodiumAlnylam Pharms32032
XcopricenobamateSk Life Science72330
Fetrojcefiderocol sulfate tosylateShionogi28028
Amiodaroneamiodarone hydrochlorideSandoz12012
ApremilastapremilastDr Reddys Labs606
AllopurinolallopurinolVintage Pharms404
Toujeoinsulin glargine recombinantSanofi Us Services303
ExservanriluzoleAquestive Therap202
ReditrexmethotrexateCumberland Pharms102
StelaraustekinumabCentocor Ortho Biotech112
FulvestrantfulvestrantHBT Labs101
Memantinememantine hydrochlorideSun Pharma101
Exemair polymer-type aGiskit B.V.101
Oxycontinoxycodone hydrochloridePurdue Pharma101
Depakotedivalproex sodiumAbbVie101

The most mentioned approval this month, with 48 mentions, was Global Blood Therapeutic’s Oxbryt (voxeltor). This was approved for the treatment of sickle cell disease (SCD) in adults and children 12 years old and older. A Canadian physician called the approval of Oxbryt, along with crizanlizumab, a ‘New era of hope’ for people living with SCD which was reposted by five other HCPs with others also being positive saying that it is ‘Good news’ and ‘breakthrough therapy’.

But among the positivity there were five HCPs that expressed that they couldn’t believe it had been approved with ‘Unvalidated surrogate endpoint’.

The second most mentioned product was Genentech’s Tecentriq (atezolizumab) for the treatment of NSCLC. HCPs shared news referencing the IMpower130 clinical trial and the data that led to the approval. Stephen Liu’s post was retweeted six times by his peers, while the product was mentioned 38 times in total by HCPs over the period.

HCPs were also positive towards the approval of Givlaari (givosiran sodium) by Alnylam saying that this is a landmark event for Alnylam and that this is a ‘big day’. Five HCPs shared the Alnylam post celebrating the news of the new approval.

We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge, or by signing up to our monthly eJournal.


‘A new hope’ found in the FDA approvals of Entresto and Farxiga

Methodology notes:

  • Data for this research was analysed from the online Twitter conversations of HCPs talking about FDA approvals in English language (all other languages are available), between November 1 – December 10 2019.
  • Between November 1 – December 10 2019, 1,519 HCPs shared posted about FDA approvals 2,099 times all over the world.
  • The table refers only to approvals that occurred between November 1 – December 10 2019. Mentions of approvals before November 1 were not included.
  • HCPs mention brand and compound names when discussing FDA approvals. Approvals may include multiple compounds.

View all articles >

Meet the Author

Nathan Cripps

Suggested next

14.11.2022 | Article

Product Launch Tracker: HCPs share optimism for approvals in heart failure, obesity and multiple myeloma

HCP's shared the news on product approvals for issues like obesity, multiple myeloma, etc.

By Paul Cranston and Tomi Shobande

14.04.2022 | Article

HCPs show concern for racial inequity issues in sickle cell treatment

This is a big issue as SCD is one of the most prevalent genetic diseases, and thus raises...

By Francesca Gan

View all articles >